2013 ACR/ARHP Annual Meeting

October 25-30, 2013. San Diego, CA.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2456

Prevalence Of Overweight and Obesity and The Relation To Disease Activity, Physical Function and Quality Of Life In Patients With Axial Spondyloarthritis
Abstract Number: 345

Prevalence Of Peri-Articular Manifestations (Enthesitis and Dactylitis) and Disease Activity In Psoriatic Arthritis Patients: Impact Of Treatment With TNF Inhibitors In a Real-World Canadian Population
Abstract Number: 516

Prevalence Of Seronegative Sjogren’s Syndrome: A Comparative Study From The Sjogren’s International Collaborative Clinical Alliance (SICCA) Cohort
Abstract Number: 1518

Prevalence Of Spondylarthritis In Individuals Needing To Purchase An Orthopedic Mattress Because Of Chronic Back Pain
Abstract Number: 1115

Prevalence Of Structural and Inflammatory Sacroiliitis, Assessed Using Computed Tomography and MR Imaging, In Inflammatory Bowel Disease: A Retrospective Study In 78 Patients
Abstract Number: 2886

Prevalence Of Structural Lesions On MRI Of The Sacroiliac Joints In Patients With Early Axial Spondyloarthritis and Patients With Back Pain
Abstract Number: 2884

Prevalence Of Structural Lesions Seen On MRI-Spine In Patients With (Possible) Axial Spondyloarthritis (axSpA) Included In The SPACE-Cohort
Abstract Number: 1549

Prevalence Of Syndesmophytes In Patients With Chronic Back Pain Suspected Of Axial Spondyloarthritis (axSpA) Not Fulfilling The Modified New York (mNY) Criteria
Abstract Number: 1071

Prevalence Of Systemic Lupus Erythematosus and Lupus Nephritis In The United States: Analysis Of Commercial and Public Insurance Billing Data
Abstract Number: 1248

Prevalence Of Vitamin D Inadequacy In European Postmenopausal Women Aged Over 80 Years
Abstract Number: 2465

Prevelance Of Inflammatory Back Pain and Axial Spondyloarthritis Among University Employees In Izmir, Turkey
Abstract Number: 2144

Prevention Of Radiological Progression In Patients With Primary Knee Osteoarthritis With Strontium Ranelate
Abstract Number: 1660

Primary Central Nervous System Vasculitis: Treatment and Course
Abstract Number: 1537

Primary & Subsequent Orthopedic Surgeries More Common In Juvenile Vs. Adult-Onset Ankylosing Spondylitis
Abstract Number: 1866

Primary Human Cell BioMAP^® Profiling Of Methotrexate, Tocilizumab, Adalimumab, and Tofacitinib Reveals Different Mechanisms Of Action With Distinct Phenotypic Signatures

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].